Insider buying last 90 days
No open-market insider purchases were filed for ASTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ASTH insider filing, plotted on the chart in Gekko.Open ASTH in Gekko
NASDAQ: ASTH
Astrana Health (ASTH) Stock Analysis & Forecast
Oct 12 close
$38.40+0.85 (+2.3%)
Gekko Brief
AI summaryOct 12 closeAstrana Health shares have been in focus this week around confirmation that third quarter results will be released, alongside continued commentary on its earnings surprise history and valuation. Wall Street coverage reiterates a "Moderate Buy" rating, with ten brokerages covering the stock, two rating it hold and eight rating it buy. A legal investigation into the company by a law firm was also reported. Separately, comparisons with peer Tenet Healthcare circulated, weighing profitability, earnings and valuation.
ASTH closed at $38.40, up 2.3%, trading above both its 50-day average of $37.05 and its 200-day average of $33.09, with the 50-day above the 200-day. The GekkoIndex reads 53.4, placing the stock in the Neutral zone, though the index has slipped 5.3 points over five sessions. Shares sit 24.1% below the Gekko Fair Value of $50.61.
The next earnings report is scheduled for 5 November 2026, after the close, 24 days away and within a typical 20-trading-day holding window; the prior release beat estimates with non-GAAP EPS of $0.74 against a $0.65 estimate, producing an 11.5% reaction. No insider, Congress or unusual options activity appears in the respective windows. Seasonally, the next 20 trading days have averaged a 1.8% return over 5 years, rising in 3 of those years. Consensus analyst target stands at $51.67, implying 34.6% upside per that consensus.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Astrana Health price vs fair value
Close $38.40200-day averageGekko Fair Value $50.61
Astrana Health quick facts
- Market cap
- $1.90B
- P/E ratio
- 43.2
- Forward P/E
- 9
- EPS, TTM
- $0.83
- Revenue, TTM
- $3.84B
- Profit margin
- 1.1%
- Dividend yield
- —
- Beta
- 1.03
- Volume
- 294,544 avg 452,041
- 1-year return
- +26.2%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±11.6%
- 50-day average
- $37.05
- 200-day average
- $33.09
- Next earnings
- Nov 5 after close
- Shares outstanding
- 49.60M
Astrana Health swing-trade checklist
Astrana Health scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $38.40 is above the 50-day ($37.05) and 200-day ($33.09) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53.4, Neutral
Reading 53.4 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
24.1% below
Price is 24.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.8% on average
From this point in the calendar, the next 20 trading days averaged +1.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Astrana Health stock chart and price history
Astrana Health closed at $38.40 on Oct 12, 2026, +26.2% over the past year, inside a 52-week range of $18.08 to $51.60.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.1%
- 3 months
- −21.6%
- 6 months
- +33.0%
- 1 year
- +26.2%
The full ASTH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ASTH in Gekko
Follow Astrana Health through every session
Put ASTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ASTH in GekkoFree for 7 days. No credit card required.
Astrana Health GekkoIndex: the smart money zone
Astrana Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.4, in the Neutral zone, down 5.3 points over five sessions.
53.4Neutral
Down 5.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 69 | +0.4% | +3.5% | ||
| Accumulation | 208 | +1.7% | +5.3% | ||
| Neutral (current zone) | 334 | −1.0% | −1.5% | ||
| Distribution | 67 | +3.5% | +4.5% | ||
| Selling | 4 | Too few readings yet | |||
Average ASTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ASTH price, zone by zone.Track ASTH in Gekko
Is Astrana Health stock overvalued? Gekko Fair Value
Astrana Health trades 24.1% below Gekko Fair Value of $50.61, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Astrana Health shares are worth, recalculated every trading day.
$50.61
Gekko Fair Value, Oct 10, 2026
24.1% Undervalued
At the end of Aug 2026 the price was 29.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ASTH in Gekko
Astrana Health insider and Congress trading
No open-market insider purchases were filed for Astrana Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ASTH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ASTH, plotted on the chart in Gekko.Open ASTH in Gekko
Buybacks
Astrana Health has been buying back its own shares.
- Latest authorization
- $100.0M, Mar 2, 2026
- Bought back, quarter ended Jun 30, 2026
- $4.36M
- As a share of market cap
- 0.23%
- Trailing four quarters
- $23.21M
From company filings.
Astrana Health earnings: next date and track record
Astrana Health reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.46
- Revenue estimate
- $1.02B
6 of 8reports beat the EPS estimate
±17.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 7, 2026 AI summary
- What they said
- Astrana Health reported Q1 2026 revenue of $965.1 million, up 56% year-over-year, with adjusted EBITDA of $66.3 million, up 82% year-over-year. Non-GAAP EPS was $0.74, up 76%, and free cash flow exceeded $64 million. The company achieved net leverage of 2.3x, ahead of its 24-month delevering target hit in just 3 quarters. Growth was driven by new full-risk contracts, disciplined medical cost management, and AI-enabled platform integration.
- Guidance
- Management anticipates ending the year at or below 2x net leverage, implying 2.2x at the midpoint of full year guidance. New full-risk contracts continue tracking in line with underwriting expectations, supporting continued disciplined growth.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | $0.74 est $0.65 | $965.1M est $949.2M | +11.5% |
| Mar 2, 2026 | $0.42 est $0.10 | $950.5M est $930.4M | +20.6% |
| Nov 6, 2025 | $0.01 est $0.47 | $956.0M est $930.5M | −23.2% |
| Aug 7, 2025 | $0.19 est $0.35 | $654.8M est $943.7M | +28.7% |
| May 8, 2025 | $0.44 est $0.33 | $620.4M est $630.7M | −7.6% |
| Feb 27, 2025 | $0.37 est $0.21 | $665.2M est $617.2M | −27.7% |
| Nov 7, 2024 | $0.33 est $0.32 | $478.7M est $613.0M | −21.1% |
| Aug 7, 2024 | $0.40 est $0.39 | $486.3M est $440.8M | −1.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Astrana Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Astrana Health is $51.67, +34.6% from the last close, from 9 firms rating the stock in the last 90 days.
$51.67consensus 12-month target, +34.6% from the last close
Now $38.40Avg $51.67
Low $41High $65
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Barclays | $53 | +38.0% |
| Oct 1 | Freedom Capital Markets | $50 | +30.2% |
| Sep 29 | Truist Financial | — | — |
| Sep 15 | Oppenheimer | $53 | +38.0% |
| Aug 28 | Barclays | $53 | +38.0% |
−1.5%average 20-day move after past Neutral readings
+1.8%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Astrana Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Astrana Health averaged +1.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.3% | 4 of 5 |
| Next 10 trading days | −0.1% | 2 of 5 |
| Next 15 trading days | +0.2% | 2 of 5 |
| Next 20 trading days | +1.8% | 3 of 5 |
| Next 30 trading days | −4.6% | 1 of 5 |
For scale, ASTH’s typical 20-trading-day move in either direction is about 11.6%.
Astrana Health market cap and key statistics
Astrana Health’s market cap is $1.90B, with a P/E ratio of 43.2 and revenue of $3.84B over the last twelve months.
Valuation
- Market cap
- $1.90B
- P/E ratio
- 43.2
- Forward P/E
- 9
- EPS, TTM
- $0.83
- Gekko Fair Value
- $50.61
Trading
- Volume
- 294,544
- Avg volume, 20 days
- 452,041
- 52-week high
- $51.60
- 52-week low
- $18.08
- Shares outstanding
- 49.60M
Financials
- Revenue, TTM
- $3.84B
- Profit margin
- 1.1%
- Return on equity
- 6.9%
- Quarterly earnings growth, YoY
- +110.5%
Risk and income
- Beta
- 1.03
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±11.6%
Astrana Health stock news this week
6 headlines about Astrana Health from the past week, newest first, each linking to the publisher.
- Is It Too Late to Buy Astrana Health Inc (ASTH) After 4.7% Rally? GF Value Says UndervaluedGuruFocus, Oct 9
- Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference CallPRNewsWire, Oct 9
- Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates AgainZacks Investment Research, Oct 9
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTHPRNewsWire, Oct 8
- Astrana Health, Inc. (NASDAQ:ASTH) Stock Rated “Moderate Buy” by Wall Street AnalystsDefense World, Oct 8
- Astrana Health (ASTH): Buy, Sell, or Hold Post Q2 Earnings?FinancialContent, Oct 8
Astrana Health peers
Astrana Health’s 2 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| DGXQuest Diagnostics | Neutral | 5.8% above |
| NRCNational Research | Accumulation | 6.3% above |
A peer links to its own page where one exists.
Astrana Health stock FAQ
What is Astrana Health’s market cap?
Astrana Health’s market cap is $1.90B at the Oct 12, 2026 close of $38.40, with 49.60M shares outstanding. The shares trade on a P/E ratio of 43.2.
What is the Astrana Health stock forecast?
The consensus analyst 12-month price target for Astrana Health is $51.67, +34.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Astrana Health stock overvalued or undervalued?
On Gekko’s estimate Astrana Health is undervalued: the Oct 12, 2026 close of $38.40 is 24.1% below Gekko Fair Value of $50.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Astrana Health report earnings next?
Astrana Health is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.46 per share on revenue of $1.02B. Astrana Health beat the earnings estimate in 6 of its last 8 reports, moving 17.7% on average across the report.
What is Astrana Health’s 52-week high and low?
Astrana Health’s 52-week high is $51.60 and its 52-week low is $18.08; it closed at $38.40 on Oct 12, 2026, +26.2% over the past year. Over the last five years the shares peaked at $133.23 on Nov 15, 2021.
Is Astrana Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Astrana Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.